FDA Alert: Abiomed Impella Blood Pump Urgent Recall
Controller may fail to detect the Impella deviceAbiomed Impella blood pump controllers
Controller May Fail to Detect Device
Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when connected.
This malfunction could result in inadequate cardiac support, which is especially dangerous for patients in cardiogenic shock.
Affected Products, Product Codes, UDI-DIs, and Serial Numbers (click on the link to download a list.)
Key Details
- Issue: The controller may not recognize the connected pump during startup or transfer between consoles.
- No visual alarm appears on screen to indicate a problem.
- Reported Cases: 3 patient deaths have been linked to this issue as of June 13; no serious injuries reported.
- Impacted Devices: All AICs across the Abiomed Impella pump line.
Recommended Actions
- Always have a backup AIC available.
- If the pump isn’t detected within 20 seconds:
- Switch back to the previous console.
- Reboot the non-responsive console.
- Start the case on a different AIC if needed.
- Distribute this alert to all relevant clinical staff and facilities.
- Forward notice to any facility that received affected products.
Why It Matters
Failure to detect the pump could lead to delayed or absent hemodynamic support, putting critically ill patients at high risk.
For questions or to report adverse events, contact Abiomed at (978) 646-1400.
The FDA is actively reviewing this high-risk issue and will provide updates here as more information becomes available.
Read more about Mechanical Circulatory Support (MCS) devices
Urgent Action Required – Baxter LIFE2000 System
Software issue can cause potential harm or death On March 10, the US Food and Drug Administration (FDA) announced that Baxter International Inc. has issued an urgent medical device correction for its LIFE2000 Ventilation System. An issue with the device’ software may...
FDA Approval for Cancer Treatment Aid
The Food and Drug Administration (FDA) on 12 December 2022 announced the approval of Agilent's Resolution CTDX FIRST, a new in vitro diagnostic (IVD) medical device for use in the detecting a specific mutation in the KRAS gene in circulating cell-free DNA. This test...
FDA Posts Warning Letter to MicroVention Costa Rica
Identifies several violations of the FD&C Act and QSR On February 7, FDA issued a warning letter it had sent to MicroVention Costa Rica SRL on September 30, 2022. The company is a subsidiary of MicroVention Inc., a medical device company based in Tustin,...